Literature DB >> 8018300

Adverse effects and drug interactions of clinical importance with antiviral drugs.

D J Morris1.   

Abstract

Most antiviral drugs are nucleoside analogues with potential teratogenic, embryotoxic, carcinogenic and antiproliferative activities. They must be administered with caution during pregnancy, because some are known teratogens (e.g. amantadine) and a similar propensity cannot be entirely excluded for others (e.g. aciclovir). Their adverse effects mostly involve bone marrow depression (e.g. granulocytopenia with ganciclovir, anaemia with zidovudine) or neurotoxicity (e.g. seizures with interferon-alpha, peripheral neuropathy with zalcitabine), although gastrointestinal effects are also seen. Idiosyncratic reactions include didanosine-induced acute pancreatitis. Only inosine pranobex is largely free from toxicity. Idoxuridine must be administered topically, given the severity of its systemic adverse effects. Drug interactions involving antiviral agents mostly reflect shared toxicity with other agents (e.g. neutropenia with ganciclovir and zidovudine, pancreatitis with didanosine and alcohol), although renal excretion or hepatic metabolism may be implicated. Given the possibility of severe adverse reactions and drug interactions, antiviral chemotherapy should only be used for potentially serious virus infections. Topical administration avoids systemic adverse effects but not mutagenic risks, and may result in exposure of individuals other than the patient (e.g. aerosolised ribavirin).

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8018300     DOI: 10.2165/00002018-199410040-00002

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  34 in total

1.  Antiviral chemoprophylaxis for cytomegalovirus infection.

Authors:  D J Morris
Journal:  J Antimicrob Chemother       Date:  1988-10       Impact factor: 5.790

2.  Possible drug interaction during therapy with azidothymidine and acyclovir for AIDS.

Authors:  M C Bach
Journal:  N Engl J Med       Date:  1987-02-26       Impact factor: 91.245

3.  Acute interstitial nephritis with the nephrotic syndrome following recombinant leukocyte a interferon therapy for mycosis fungoides.

Authors:  S D Averbuch; H A Austin; S A Sherwin; T Antonovych; P A Bunn; D L Longo
Journal:  N Engl J Med       Date:  1984-01-05       Impact factor: 91.245

4.  Common pathways of interferon and hormonal action.

Authors:  J E Blalock; J D Stanton
Journal:  Nature       Date:  1980-01-24       Impact factor: 49.962

5.  Pregnancy outcomes following systemic prenatal acyclovir exposure--June 1, 1984-June 30, 1993.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1993-10-22       Impact factor: 17.586

6.  Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome.

Authors:  J E Groopman; R T Mitsuyasu; M J DeLeo; D H Oette; D W Golde
Journal:  N Engl J Med       Date:  1987-09-03       Impact factor: 91.245

7.  Toxicity of adenine arabinoside in humans.

Authors:  A H Ross; A Julia; C Balakrishnan
Journal:  J Infect Dis       Date:  1976-06       Impact factor: 5.226

8.  Randomized trial of recombinant alpha 2b-interferon with or without indomethacin in patients with metastatic malignant melanoma.

Authors:  R L Miller; R G Steis; J W Clark; J W Smith; E Crum; J E McKnight; M J Hawkins; M J Jones; D L Longo; W J Urba
Journal:  Cancer Res       Date:  1989-04-01       Impact factor: 12.701

Review 9.  Interactions and toxicities of drugs used in patients with AIDS.

Authors:  B L Lee; S Safrin
Journal:  Clin Infect Dis       Date:  1992-03       Impact factor: 9.079

10.  A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. The Terry Beirn Community Programs for Clinical Research on AIDS.

Authors:  D I Abrams; A I Goldman; C Launer; J A Korvick; J D Neaton; L R Crane; M Grodesky; S Wakefield; K Muth; S Kornegay
Journal:  N Engl J Med       Date:  1994-03-10       Impact factor: 91.245

View more
  7 in total

Review 1.  Cytomegalovirus antivirals and development of improved animal models.

Authors:  Alistair McGregor; K Yeon Choi
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-09-01       Impact factor: 4.481

2.  Opportunities for diagnosing cytomegalovirus in pulmonary infections.

Authors:  D J Morris
Journal:  Thorax       Date:  1995-01       Impact factor: 9.139

Review 3.  Drug interactions with antiviral drugs.

Authors:  A M Taburet; E Singlas
Journal:  Clin Pharmacokinet       Date:  1996-05       Impact factor: 6.447

4.  Type I interferons mediate pancreatic toxicities of PERK inhibition.

Authors:  Qiujing Yu; Bin Zhao; Jun Gui; Kanstantsin V Katlinski; Angela Brice; Yan Gao; ChangHong Li; Jake A Kushner; Constantinos Koumenis; J Alan Diehl; Serge Y Fuchs
Journal:  Proc Natl Acad Sci U S A       Date:  2015-12-01       Impact factor: 11.205

5.  Metabolism of cyclopropavir and ganciclovir in human cytomegalovirus-infected cells.

Authors:  Brian G Gentry; John C Drach
Journal:  Antimicrob Agents Chemother       Date:  2014-02-10       Impact factor: 5.191

6.  Molecular Insights of Hyaluronic Acid-Hydroxychloroquine Conjugate as a Promising Drug in Targeting SARS-CoV-2 Viral Proteins.

Authors:  R Thirumalaisamy; V Aroulmoji; Muhammad Nasir Iqbal; M Deepa; C Sivasankar; Riaz Khan; T Selvankumar
Journal:  J Mol Struct       Date:  2021-04-13       Impact factor: 3.196

Review 7.  Mono- and combinational drug therapies for global viral pandemic preparedness.

Authors:  Aleksandr Ianevski; Rouan Yao; Ronja M Simonsen; Vegard Myhre; Erlend Ravlo; Gerda D Kaynova; Eva Zusinaite; Judith M White; Stephen J Polyak; Valentyn Oksenych; Marc P Windisch; Qiuwei Pan; Eglė Lastauskienė; Astra Vitkauskienė; Algimantas Matukevičius; Tanel Tenson; Magnar Bjørås; Denis E Kainov
Journal:  iScience       Date:  2022-03-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.